|Chemical and physical data|
|Molar mass||453.36 g·mol−1|
|3D model (JSmol)|
BAY 59-3074 is a drug which is a cannabinoid receptor partial agonist developed by Bayer AG. It has analgesic effects and is used in scientific research. It is orally active in animals, and has modest affinity for both CB1 and CB2 receptors, with Ki values of 48.3nM at CB1 and 45.5nM at CB2. In vitro: analgesic, antihyperalgesic, and antiallodynic properties in rat models of acute and chronic pain. The reference concentration is 10 μM. In vivo: administration of BAY 59-3074 (ED50 value: 0.41 mg/kg).Orally active CB1 agonist in vivo.
- De Vry, J.; Denzer, D.; Reissmueller, E.; Eijckenboom, M.; Heil, M.; Meier, H.; Mauler, F. (2004). "3-2-cyano-3-(trifluoromethyl)phenoxyphenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects". The Journal of Pharmacology and Experimental Therapeutics. 310 (2): 620–32. doi:10.1124/jpet.103.062836. PMID 15140913.
- De Vry, J.; Jentzsch, K. R. (2004). "Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat". European Journal of Pharmacology. 505 (1–3): 127–33. doi:10.1016/j.ejphar.2004.10.012. PMID 15556145.
- "Bay 59-3074". MedChemExpress.